Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Docbot
AddedMar 20, 2024
UpdatedJul 3, 2026
Docbot

Docbot

Acquired

Docbot is a healthtech company that develops AI software for real-time lesion detection in colonoscopy and endoscopy.

Accelerator
Y Combinator logoY CombinatorW19
Overview
Compare
Fundraising
Employees

Docbot's Ultivision platform applies machine learning to colonoscopy and endoscopy video, analyzing more than 100 frames per second to flag adenomas and other lesions in real time. The system is designed to assist gastroenterologists in detecting abnormalities that can be missed during visual inspection, with the goal of improving colon-cancer screening and reducing interval cancers. Docbot has also trained the platform to assess ulcerative colitis severity from full-length endoscopy videos.

The company's intended customers are gastroenterology practices, endoscopy clinics, and the physicians performing colonoscopies. It competes in the medical imaging and AI-assisted endoscopy market alongside FDA-cleared systems such as Medtronic's GI Genius. Docbot is positioning Ultivision for regulatory clearance through a U.S. pivotal trial intended to support a De Novo submission to the FDA.

Docbot - Similar Companies

Iterative Scopes logo

Iterative Scopes

BioticsAI logo

BioticsAI

biotics.ai

Bot MD logo

Bot MD

botmd.io

Altris.AI logo

Altris.AI

altris.ai

Docus logo

Docus

docus.ai

Crosscope logo

Crosscope

crosscope.com

Scanbase logo

Scanbase

scanbase.com

Hippocratic AI logo

Hippocratic AI

hippocraticai.com

Retrieve Medical logo

Retrieve Medical

Bot Image logo

Bot Image

Adentris logo

Adentris

adentris.com

Readily logo

Readily

readily.co

Vitazi.ai logo

Vitazi.ai

vitazi.ai

Carpl.Ai logo

Carpl.Ai

carpl.ai

Adra logo

Adra

adra.ai

Docbot - Quick Facts

Who are Docbot's competitors?

Companies similar to Docbot include Iterative Scopes, BioticsAI, Bot MD and Altris.AI.

When was Docbot's last funding round?

Docbot's most recent funding round was for $150k (USD) in January 2019.

How much has Docbot raised to-date?

As of Jan 1, 2019, Docbot has raised a total of $150k (USD).

Docbot - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Revenue
  • Recurring
  • SaaS
  • Software
Customer
  • Enterprise
Main Product
  • Medical Software
Tags
  • Healthcare
  • Healthtech